ArticleStem cell research2011
Cell sourcing for bone tissue engineering: amniotic fluid stem cells have a delayed, robust differentiation compared to mesenchymal stem cells.
Article in Stem cell research, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed.
- A Systematic Review on Amnion as a Cell Delivery Scaffolding Material for Cartilage Regeneration in Pre-Clinical and Clinical Studies.Bioengineering (Basel, Switzerland) · 2026Review
- Evaluating Mineral Deposition in Bone-Regenerative Collagen-Based Scaffolds Using High-Resolution microCT and 3D Computational Segmentation.Current protocols · 2026Article
- An In Vivo Assessment of Different Mesenchymal Stromal Cell Tissue Types and Their Differentiation State on a Shape Memory Polymer Scaffold for Bone Regeneration.Journal of biomedical materials research. Part B, Applied biomaterials · 2024Article
- Amniotic fluid characteristics and its application in stem cell therapy: A review.International journal of reproductive biomedicine · 2022Review
- A comprehensive review on methods for promotion of mechanical features and biodegradation rate in amniotic membrane scaffolds.Journal of materials science. Materials in medicine · 2022Review
- The effects of cryopreserved human amniotic membrane on fracture healing: Animal study.Acta orthopaedica et traumatologica turcica · 2019Article
- Osteogenic Potential of Multipotent Adult Progenitor Cells for Calvaria Bone Regeneration.Advances in medicine · 2016Article
- A Mini Overview of Isolation, Characterization and Application of Amniotic Fluid Stem Cells.International journal of stem cells · 2015Review
- A novel method for differentiation of human mesenchymal stem cells into smooth muscle-like cells on clinically deliverable thermally induced phase separation microspheres.Tissue engineering. Part C, Methods · 2015Article
- Perinatal stem cells: A promising cell resource for tissue engineering of craniofacial bone.World journal of stem cells · 2015Review
- Comparative investigation of human amniotic epithelial cells and mesenchymal stem cells for application in bone tissue engineering.Stem cells international · 2015Article
- Microcomputed tomography: approaches and applications in bioengineering.Stem cell research & therapy · 2014Review
- HB-EGF augments the ability of mesenchymal stem cells to attenuate intestinal injury.Journal of pediatric surgery · 2014Article
- Role of amniotic fluid mesenchymal cells engineered on MgHA/collagen-based scaffold allotransplanted on an experimental animal study of sinus augmentation.Clinical oral investigations · 2013Article
- Synergistic effects of HB-EGF and mesenchymal stem cells in a murine model of intestinal ischemia/reperfusion injury.Journal of pediatric surgery · 2013Article
- Differentiation patterns of embryonic stem cells in two- versus three-dimensional culture.Cells, tissues, organs · 2013Article
- Heparin-binding epidermal growth factor-like growth factor protects mesenchymal stem cells.The Journal of surgical research · 2012Article
- Amniotic fluid stem cells and their application in cell-based tissue regeneration.International journal of fertility & sterility · 2012Review
- Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
Cell based therapies for bone regeneration are an exciting emerging technology, but the availability of osteogenic cells is limited and an ideal cell source has not been identified. Amniotic fluid-derived stem cells (AFS) and bone-marrow derived mesenchymal stem cells (MSCs) were compared to determine their osteogenic differentiation capacity in both 2D and 3D environments. In 2D culture, the AFS cells produced more mineralized matrix but delayed peaks in osteogenic markers. Cells were also cultured on 3D scaffolds constructed of poly-ε-caprolactone for 15 weeks. MSCs differentiated more quickly than AFS cells on 3D scaffolds, but mineralized matrix production slowed considerably after 5 weeks. In contrast, the rate of AFS cell mineralization continued to increase out to 15 weeks, at which time AFS constructs contained 5-fold more mineralized matrix than MSC constructs. Therefore, cell source should be taken into consideration when used for cell therapy, as the MSCs would be a good choice for immediate matrix production, but the AFS cells would continue robust mineralization for an extended period of time. This study demonstrates that stem cell source can dramatically influence the magnitude and rate of osteogenic differentiation in vitro.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.